CD44 and glioblastoma: A TCGA-Glioma based co-expression study for CD133 and CD44 in glioblastomas (GBM) reported that CD133 module tumors were enriched for the Proneural GBM subtype, while CD44 module tumors were enriched in Mesenchymal subtype [28].